Asthma is a heterogenous disease. Treatment decisions are typically based on measures of airflow obstruction, the frequency of daytime and nighttime symptoms, and the frequency of exacerbations. FeNO is an objective biomarker of allergic airway inflammation, an indicator of asthma and other pulmonary conditions. The new ATS Clinical Practice Guidelines provide evidence-based clinical guidance on whether FeNO testing is indicated to optimize asthma treatment in patients with asthma in whom treatment is being considered. During this webinar, Dr. Philip Silkoff, will review, which questions about FeNO where considered by the ATS committee, the principal findings of the data review and the implication of FeNO testing for the asthma care.
This program has been approved for 1.00 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425, N. MacArthur Blvd, Suite 100, Irving TX 75063
Pulmonologists, PFT specialists, Pulmonary therapists